Outsourcing stem cell storage - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing stem cell storage
Stem cells — often referred to as 'the miracle cell' — have already taught the scientific community a great deal, and it is accepted that future advances in research will offer the potential for therapeutic treatments of many medical conditions; from Parkinson's disease to spinal cord injuries. The efficient storage of these unique building blocks of life must, however, be carefully considered.


Pharmaceutical Technology Europe
Volume 21, Issue 12

Why is the correct storage of stem cells so important for the future of medical innovation?


Patrick Jackson Business Development Director, Vindon Scientific (UK)
Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease. There are two broad categories of stem cells: adult stem cells (also known as somatic stem cells) and embryonic stem cells. Adult stem cells are already routinely used to treat lifethreatening conditions and are also contributing to new regenerative therapies that can be used in drug R&D.

Stem cells can be sourced from the bone marrow itself, peripheral blood and, more recently, umbilical cord blood. Stem cells from umbilical cord blood (haematopoietic stem cells) have to date been used to repair bone marrow in more than 2000 patients. In the US, cord blood has become the most frequent source of stem cells for transplantation in children. Along with ongoing research to improve the use of cord blood in stem cell transplants, a significant amount of research is being conducted to explore the application of cord blood in the field of regenerative medicine. Currently, there are ongoing clinical studies investigating the value of cord blood in the treatment of brain injury, cerebral palsy, Type 1 diabetes, heart disease and critical limb ischaemic.

The market for stem cells is very much in its infancy, but there is little doubt that stem cell storage will be the norm in years to come, not just in the private sector, but also for public health services and other public arenas.


(Vindon Scientific.)
Stem cells from umbilical cord blood are one of the most commonly banked types of human tissue. They can be stored in bags or vials, or the whole blood sample can be stored. Quality assurance standards are also crucial, which is particularly relevant given that cord blood stem cells are likely to play such an important part in cellular therapies in the future. In fact, it is estimated that by 2015, there will be up to 10000 cord blood transplants worldwide per year using banked cord blood, which is why it is important to build repositories for the storage of cells to guarantee continued successes.

New sources of stem cells from adipose tissue (fat), children's milk teeth and even hair are regularly being identified and stored under cryogenic conditions that preserve materials unaltered; this usually involves temperatures from 160 C to 190 C. Liquid nitrogen is the most logical choice for storage at temperatures below 130 C, but there are risks associated with its use. The extremely low temperature of the liquid can cause severe burnlike damage to the skin either by contact with the fluid, surfaces cooled by the fluid or evolving gases. Large volumes of nitrogen gas are evolved from small volumes of liquid nitrogen. This can easily replace normal air in poorly ventilated areas leading to the danger of asphyxiation. The risk of injury is moderate, with cryogenic burns the most likely injury; however in exceptional circumstances when large amounts of material are spilled in an enclosed space, asphyxiation may be fatal.

To ensure there is no crosscontamination with the stored samples, it is generally recommended that materials are accommodated in the vapour phase above the actual nitrogen, where temperatures are in the region of 150 C down to 197 C. Crosscontamination of biological samples when immersed in the liquid nitrogen may mean viruses and bacteria can invade the stored samples.

Industry experts believe that the use of drystore freezers, specifically designed as vapour phase storage systems, offer exceptional sample security; a slight positive pressure in the sample chamber will circulate out any pathogens; and operator safety is ensured as the storage area is completely free of liquid nitrogen, which is housed in a jacket surrounding the chamber. Temperature performance to 190 C can be achieved well below the level required to keep materials in firstclass condition.

By storing stem cells taken from a baby's umbilical cord, it is now possible for parents to insure their child's future health against diseases such as cancer, diabetes, cardiovascular problems and blood disorders.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here